Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS)
- PMID: 21762134
- DOI: 10.1111/j.1526-4610.2011.01945.x
Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS)
Abstract
Objective: To evaluate and compare healthcare resource use and related costs in chronic migraine and episodic migraine in the USA and Canada.
Background: Migraine is a common neurological disorder that produces substantial disability for sufferers around the world. Several studies have quantified overall costs associated with migraine in general, with recent estimates ranging from $581 to $7089 per year. Although prior studies have characterized the clinical and humanistic burden of chronic migraine relative to episodic migraine, to the best of our knowledge only 1 previous study has compared chronic migraine and episodic migraine healthcare costs. The purpose of this study was to quantify and compare the direct medical costs of chronic migraine and episodic migraine using medical resource use data collected as part of the International Burden of Migraine Study.
Methods: Cross-sectional data were collected from respondents in 10 countries via a Web-based survey. Respondents were classified as chronic migraine (≥15 headache days/month) or episodic migraine (<15 headache days/month). Data collection included socio-demographic and clinical characteristics and medical resource use for headache (clinician and emergency department visits and hospitalizations over the preceding 3 months and medications over the preceding 4 weeks). Unit cost data were collected outside of the Web-based survey using publicly available sources and then applied to resource use profiles. Cost estimates are presented in 2010 US and Canadian dollars.
Results: In this manuscript, the analysis included data from respondents with migraine in the USA (N=1204) and Canada (N=681). The most common medical services utilized by all respondents included headache-specific medication, healthcare provider visits, emergency department visits, and diagnostic testing. In the USA, approximately one-quarter (26.2%) of chronic migraine participants vs 13.9% of episodic migraine participants reported visiting a primary care physician in the preceding 3 months (P<.001). In Canada, one-half (48.2%) of chronic migraine participants had a primary care physician visit, compared with 12.3% of episodic migraine subjects (P< .0001). Total mean headache-related costs for participants with chronic migraine in the USA were $1036 (±$1334) over 3 months compared to $383 (±807, P< .001) for persons with episodic migraine. In Canada, total mean headache-related costs among chronic migraine subjects were $471 (±1022) compared to $172 (±920, P< .001) for episodic migraine subjects.
Conclusions: Chronic migraine was associated with higher medical resource use and total costs compared to episodic migraine. Therapies that reduce headache frequency could become important approaches for containing or reducing headache-related medical costs.
© 2011 American Headache Society.
Similar articles
-
Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.Headache. 2009 Apr;49(4):498-508. doi: 10.1111/j.1526-4610.2009.01369.x. Epub 2009 Feb 25. Headache. 2009. PMID: 19245386
-
Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.J Med Econ. 2013;16(4):490-9. doi: 10.3111/13696998.2013.770748. Epub 2013 Feb 11. J Med Econ. 2013. PMID: 23356422
-
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey.Headache. 2016 Feb;56(2):306-22. doi: 10.1111/head.12755. Epub 2016 Feb 1. Headache. 2016. PMID: 26833083
-
The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies.Headache. 2013 Mar;53(3):427-36. doi: 10.1111/head.12074. Epub 2013 Mar 7. Headache. 2013. PMID: 23470015 Review.
-
The economic cost of migraine. Present state of knowledge.Neurology. 1994 Jun;44(6 Suppl 4):S56-62. Neurology. 1994. PMID: 8008226 Review.
Cited by
-
The effect of greater occipital nerve block on amplification of somatic symptoms and anxiety and depression levels in chronic migraine.Acta Neurol Belg. 2024 May 30. doi: 10.1007/s13760-024-02585-y. Online ahead of print. Acta Neurol Belg. 2024. PMID: 38814378
-
Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview.J Headache Pain. 2024 Feb 5;25(1):13. doi: 10.1186/s10194-024-01720-7. J Headache Pain. 2024. PMID: 38311745 Free PMC article. Review.
-
Health equity, care access and quality in headache - part 1.J Headache Pain. 2024 Jan 29;25(1):12. doi: 10.1186/s10194-024-01712-7. J Headache Pain. 2024. PMID: 38281917 Free PMC article. Review.
-
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.J Manag Care Spec Pharm. 2023 Oct;29(10):1119-1128. doi: 10.18553/jmcp.2023.29.10.1119. J Manag Care Spec Pharm. 2023. PMID: 37776119 Free PMC article.
-
Economic burden of chronic migraine in OECD countries: a systematic review.Health Econ Rev. 2023 Sep 1;13(1):43. doi: 10.1186/s13561-023-00459-2. Health Econ Rev. 2023. PMID: 37656228 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical